EPIM
ALNY icon

Evelyn Partners Investment Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Evelyn Partners Investment Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$57.9K Hold
175
– – ﹤0.01% 270
2025
Q4 		$69.6K Hold
175
– – ﹤0.01% 265
2025
Q3 		$79.8K Sell
175
-75
-30% -$30.5K ﹤0.01% 257
2025
Q2 		$81.5K Hold
250
– – ﹤0.01% 252
2025
Q1 		$67.5K Hold
250
– – ﹤0.01% 260
2024
Q4 		$58.8K Buy
+250
New +$65.7K ﹤0.01% 269

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Evelyn Partners Investment Management's ALNY Position: Q1 2026 in Review

Evelyn Partners Investment Management held its Alnylam Pharmaceuticals (ALNY) position steady in Q1 2026 at 175 shares worth $57.9K. The position accounts for ﹤0.01% of the portfolio, ranked #270.

Evelyn Partners Investment Management first reported a position in ALNY in Q4 2024 and has held it in 6 quarters since. The position peaked at $81.5K in Q2 2025. 787 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Evelyn Partners Investment Management held 175 shares of Alnylam Pharmaceuticals worth $57.9K as of Q1 2026.
  • Evelyn Partners Investment Management left its Alnylam Pharmaceuticals share count unchanged in Q1 2026.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Evelyn Partners Investment Management's portfolio in Q1 2026, its #270 holding.
  • Evelyn Partners Investment Management first reported a position in Alnylam Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • Evelyn Partners Investment Management's Alnylam Pharmaceuticals position peaked at $81.5K in Q2 2025.
  • 787 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Evelyn Partners Investment Management's 13F filing for Q1 2026, filed 15 May 2026.